Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-&agr;2b in patients with metastatic melanoma

@article{Tarhini2017SafetyAE,
  title={Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-&agr;2b in patients with metastatic melanoma},
  author={A. Tarhini and S. Moschos and Y. Lin and H. Lin and C. Sander and Y. Yin and R. Venhaus and T. Gajewski and J. Kirkwood},
  journal={Melanoma Research},
  year={2017},
  volume={27},
  pages={342–350}
}
  • A. Tarhini, S. Moschos, +6 authors J. Kirkwood
  • Published 2017
  • Medicine
  • Melanoma Research
  • This study evaluated the safety and clinical benefit of ecromeximab (KW2871) combined with high-dose interferon-&agr;2b (HDI) in patients with metastatic melanoma. We also carried out pharmacokinetic and immune monitoring studies of this combination. This was an open-label, phase 1/2 study of ecromeximab plus HDI in patients with measurable metastatic melanoma. Eligible patients received ecromeximab-HDI combination therapy: ecromeximab administered intravenously once every 2 weeks and HDI at a… CONTINUE READING
    2 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    This was a Phase 2, open-label study of KW2871 (ecromeximab) in combination with high-dose interferon-α2b (HDI) in patients with metastatic melanoma. The primary objectives of this… Expand
    ConditionsCutaneous Melanoma, Metastatic Melanoma
    InterventionDrug

    References

    SHOWING 1-10 OF 36 REFERENCES
    Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    • 1,116
    Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
    • 1,895
    Improved survival with ipilimumab in patients with metastatic melanoma.
    • 10,634
    • PDF
    Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    • A. Scott, F. T. Lee, +21 authors L. Old
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2001
    • 78
    Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
    • 156
    Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    • 579
    How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
    • A. Tarhini, J. Kirkwood
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2012
    • 16
    Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    • M. Avril, S. Aamdal, +17 authors Y. Menu
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2004
    • 434